144 related articles for article (PubMed ID: 35700590)
21. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
23. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection.
Endo K; Sato T; Suzuki A; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
J Gastroenterol Hepatol; 2020 Sep; 35(9):1602-1609. PubMed ID: 31975438
[TBL] [Abstract][Full Text] [Related]
24. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
25. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
26. Acute myeloid leukaemia following direct acting antiviral drugs in HCV-infected patients: A 10 years' retrospective single-center study.
Scheifer C; Luckina E; Lebrun-Vignes B; Diop AA; Damais-Thabut D; Roos-Weil D; Dechartres A; Lebray P
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):102000. PubMed ID: 35933093
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
[TBL] [Abstract][Full Text] [Related]
28. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis.
Cacciola I; Russo G; Filomia R; Pitrone C; Caccamo G; Giandalia A; Alibrandi A; Stella Franzè M; Porcari S; Maimone S; Saitta C; Squadrito G; Raimondo G
Liver Int; 2021 Sep; 41(9):2059-2067. PubMed ID: 33894103
[TBL] [Abstract][Full Text] [Related]
29. Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
Yamazaki T; Joshita S; Umemura T; Usami Y; Sugiura A; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Ota M; Tanaka E
PLoS One; 2018; 13(4):e0195632. PubMed ID: 29617443
[TBL] [Abstract][Full Text] [Related]
30. Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study.
Thi Thu PN; Hoang Van D; Ngo Thi Quynh M; Tran Thi N; Pham Minh K; Pham Van L
PLoS One; 2023; 18(9):e0290235. PubMed ID: 37656689
[TBL] [Abstract][Full Text] [Related]
31. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
32. Safety of Direct-Acting Antiviral Therapy Regarding Renal Function in Post-Liver Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response-A Single-Center Study.
Peschel G; Moleda L; Baier L; Selgrad M; Schmid S; Scherer MN; Müller M; Weigand K
Transplant Proc; 2018 Jun; 50(5):1444-1450. PubMed ID: 29880368
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study.
Wu VC; Huang CH; Wang CL; Lin MH; Kuo TY; Chang CH; Wu M; Chen SW; Chang SH; Chu PH; Wu CS; Lin YS
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):507-514. PubMed ID: 37170917
[TBL] [Abstract][Full Text] [Related]
34. The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals.
Seko Y; Moriguchi M; Takahashi A; Okishio S; Kataoka S; Okuda K; Mizuno N; Takemura M; Taketani H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
Intern Med; 2020; 59(15):1811-1817. PubMed ID: 32741890
[TBL] [Abstract][Full Text] [Related]
35. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
36. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis.
Lapumnuaypol K; Pisarcik D; Putthapiban P; Sukhumthammarat W; Wijarnpreecha K; Thongprayoon C; Ungprasert P
Indian J Med Res; 2020 Dec; 152(6):562-567. PubMed ID: 34145095
[TBL] [Abstract][Full Text] [Related]
37. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
38. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
39. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
[TBL] [Abstract][Full Text] [Related]
40. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy.
Amaddeo G; Nguyen CT; Maillé P; Mulé S; Luciani A; Machou C; Rodrigues A; Regnault H; Mallat A; Laurent A; Lafdil F; Hézode C; Pawlotsky JM; Calderaro J
Liver Int; 2020 Jan; 40(1):74-82. PubMed ID: 31444947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]